NYU Langone Medical Center
New York, 10016, United States
NCT Number: NCT02106416
The purpose of this study is to develop a novel technique for integrated PET/MRI tracer kinetic analysis for urologic malignancy.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
New York, 10016, United States
Patients scheduled to undergo gadolinium-enhanced MRI for urologic malignancy will be recruited to undergo PET/MRI employing simultaneous dynamic acquisition of PET and gadolinium-chelate data sets. For initial technical development within this pilot study, analysis will be performed attempting to compute tracer delivery using inputs from an integrated MRI-perfusion analysis. Flow and permeability will be obtained from the MR perfusion analysis, which can be used to compute the inflow rate constant K1. K1, reflecting the transfer of contrast, will then be used to compute the metabolic uptake of FDG by the organ as well as of any visible tumors. A determination will be made whether this metabolic uptake is successfully computed for each case. If not, then acquisition and post-processing modifications will be made for subsequent cases.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The study population will consist of patients with known urologic cancer who are scheduled to undergo MRI with gadolinium for their routine care. Patients will be referred by the Urology or Medical Oncology Departments for participation in the study. Subjects will be selected on the basis of their willingness and ability to participate and on their likelihood of completing the study. Patients agreeing to participate will be presented with a flyer which will inform subject about the available research study and study contact information. participation is entirely voluntary, and a subject may withdraw from the study at any time. Normal volunteers will be recruited accessing the existing database of normal volunteers maintained in Radiology Research department.
Exclusion criteria
Normal MRI exclusion criteria will apply, including those on the following list. A standard MRI safety form will be used to identify potential conditions warranting exclusion.
Simultaneous PET/MRI (3T system)
Other names: Siemens Biograph mMR
Time frame: Within six months of scan completion
The inflow rate constant K1 will be calculated based on assessment of dynamic PET/MRI data.
NYU Langone Health
Other
Development of a Novel Technique for PET/MRI Tracer Kinetic Analysis for Urologic Pelvic Malignancy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06955910
Behavior, Behavioral Symptoms
Padova, Italy/Padova, Italy
View Trial DetailsNCT03345563
Bladder Cancer, Colon Cancer
New Brunswick, New Jersey, United States
View Trial DetailsNCT02704832
Adnexal Diseases, Bladder Cancer
Grenoble, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT05253053
Adenocarcinoma, Advanced Solid Tumor
Wuhu, Anhui, China
View Trial Details